Related Experiment Video
Updated: Jun 1, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
SGLT-2 Inhibitors: A Narrative Review
Dawood Shehzad1, Muhammad Hasan1, Naveen Rajpurohit2
1Internal Medicine Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer significant benefits beyond diabetes management, showing promise in treating cardiovascular and kidney diseases. Their expanding applications and increasing accessibility make them vital in modern medicine.
Area of Science:
- Pharmacology and Therapeutics
- Cardiology
- Nephrology
- Oncology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for glycemic control in type 2 diabetes.
- Emerging evidence highlights their pleiotropic effects extending beyond glucose lowering.
- These effects have significant implications for cardiovascular and renal health.
Purpose of the Study:
- To review the expanded therapeutic applications of SGLT2 inhibitors.
- To discuss their established and potential benefits in various non-diabetic conditions.
- To consider the implications of their broader use and accessibility.
Main Methods:
- Comprehensive literature review of clinical trials and observational studies.
- Analysis of pharmacological mechanisms underlying SGLT2 inhibitor action.
- Evaluation of data on cardiovascular, renal, and oncological outcomes.
Main Results:
- SGLT2 inhibitors demonstrate robust efficacy in reducing cardiovascular events and slowing the progression of chronic kidney disease.
- Evidence suggests potential benefits in managing hypertension and exploring applications in cancer therapy.
- Adverse effects and contraindications are noted but generally manageable.
Conclusions:
- SGLT2 inhibitors represent a significant therapeutic advancement with broad applications beyond diabetes.
- Their cardiovascular and renal protective effects are well-established, with emerging roles in other diseases.
- Increased accessibility through generic availability promises wider patient benefit.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
01:23Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
01:27Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K